Drugs / BMS-986453
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07333261 | Feb 2026 → Dec 2031 expected | plasma cell myeloma | Susan Bal | Recruiting | No outcome recorded |
| Phase 1 | NCT06153251 | Jan 2024 → May 2030 expected | refractory plasma cell neoplasm | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986453 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07333261 ↗ |
| Route | Intravenous | “administered by IV infusion” NCT07333261 ↗ |